Effectiveness of an Electronic Training Program for Orienting and Interpreting [18F]Flutemetamol Positron Emission Tomography (PET) Images
NCT ID: NCT01672827
Last Updated: 2014-01-24
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
276 participants
INTERVENTIONAL
2012-07-31
2012-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Computerized Cognitive Training Program for Older Persons With Mild Dementia
NCT02671630
Effects of Training Dose on Computerized Cognitive Training in Patients With Cognitive Impairment
NCT05922319
Efficacy of 1072nm Infrared Stimulation on Executive Functioning in Dementia
NCT01059877
Efficacy of the Cognitive Training Based on Location Information and Activity in People With Mild Cognitive Impairment
NCT03928613
NEUROFEEDBACK TRAINING FOR OLDER ADULTS WITH MILD COGNITIVE IMPAIRMENT: A PILOT STUDY
NCT04027725
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
[18F]Flutemetamol
[18F]Flutemetamol
No drug is administered in this intervention. These are scanned images being reviewed, previously acquired in various GE-067 studies.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
[18F]Flutemetamol
No drug is administered in this intervention. These are scanned images being reviewed, previously acquired in various GE-067 studies.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* The subject was classified as one of the following:
1. End-of-life subject who expired and underwent brain autopsy, with histochemical (HC) confirmation of brain amyloid status.
2. Subject with known/suspected normal pressure hydrocephalus (NPH) who underwent brain biopsy, with HC confirmation of brain amyloid status.
3. Elderly healthy volunteer (age ≥55).
4. Young healthy volunteer (age ≤40).
5. Subject with probable Alzheimer Disease (pAD).
6. Subject with amnestic Mild Cognitive Impairment (aMCI).
Exclusion Criteria
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GE Healthcare
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Paul Sherwin, MD
Role: STUDY_CHAIR
GE Healthcare
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GE-067-021
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.